JPRN-UMIN000030231
Completed
Phase 2
Phase2 study on the validity of initiating treatment during midtrimester for GDM patients - GDM intervention trial
ConditionsGDM
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- GDM
- Sponsor
- Yokohama City University Medical Center
- Enrollment
- 150
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50
Recruiting
Not Applicable
Phase 2 clinical study of evaluation of efficacy of switch to eribulin chemotherapy in patients with locally advanced breast cancer or metastatic breast cancer who are not responsive to combination regimen of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) and continuation of TAC chemotherapy in responding patients to TACocally advanced and/or metastatic breast cancer patientsJPRN-UMIN000015838Saitama Medical Univeristy International Medical Center40
Active, not recruiting
Phase 1
A phase II clinical trial to assess the effect of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of nonunions fractures of long bonesAtrophic pseudarthrosisMedDRA version: 21.1Level: PTClassification code 10048617Term: PseudarthrosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2013-000930-37-ESaboratorios Salvat, S.A.12
Active, not recruiting
Phase 1
Study to assess the value of a nuclear medicine procedure (Tc-99m tetrofosmin SPECT) to identify tumor recurrence in patients with brain tumors after radiation therapy.Patients with high grade brain tumorsMedDRA version: 20.0Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005573-21-HUpro-ACTINA S.A.51
Active, not recruiting
Phase 1
Study to assess the value of a nuclear medicine procedure (Tc-99m tetrofosmin SPECT) to identify tumor recurrence in patients with brain tumors after radiation therapy.Patients with high grade brain tumorsMedDRA version: 20.0Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005573-21-FRpro-ACTINA S.A.30